Company Overview
About Viridian Therapeutics
Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment.
Business Model & Competitive Advantage
Viridian's FcRn inhibitor platform addresses the treatment gap in thyroid eye disease and IgG-mediated autoimmune conditions: thyroid eye disease (affecting 50,000+ new US patients annually, associated with Graves' hyperthyroidism) causes the immune system to produce IgG antibodies that attack the thyroid-stimulating hormone receptor in orbital tissue — causing proptosis (eye protrusion), diplopia (double vision), and orbital inflammation that significantly impairs quality of life. FcRn inhibitors (blocking the neonatal Fc receptor that recycles IgG antibodies, thereby reducing circulating IgG levels and the autoantibody burden driving the disease) represent a mechanistically differentiated approach from the currently approved standard (teprotumumab/Tepezza, which targets IGF-1R). Viridian's subcutaneous formulation (self-injectable) versus teprotumumab's IV infusion provides meaningful patient convenience differentiation if clinical efficacy is comparable.
Competitive Landscape 2025–2026
In 2025, Viridian competes in the thyroid eye disease therapeutics and rare autoimmune market with Amgen/Horizon Therapeutics (NASDAQ: AMGN, Tepezza for TED, $1.9B 2023 revenue), Immunovant (NASDAQ: IMVT, FcRn inhibitor platform, $400M raised), and Argenx (NASDAQ: ARGX, efgartigimod FcRn inhibitor, $1.7B revenue) for TED and IgG-autoantibody disease FcRn inhibitor therapy market positioning. The NASDAQ listing and $636.6M cash position reflect biotech market financing strength. Y Combinator W20 backing (unusual for a clinical-stage biotech) provides organizational credibility and investor network connectivity. The 2025 strategy focuses on the veligrotug BLA submission and FDA review process, enrolling the VRDN-003 Phase 3 program, and positioning Viridian as a multi-asset rare autoimmune company beyond TED with the FcRn platform.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Viridian Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Growth Stage
Viridian Therapeutics has achieved $636.6M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Viridian Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Viridian Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Viridian Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Viridian Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →